KRAS and non-small cell lung carcinoma: Given the high frequency of the KRAS mutation and the possibility of having targeted therapies recently approved by the FDA, the use of adagrasib and sotorasib are initial alternatives in patients with non-small cell lung cancer, also showing their usefulness in patients who have progressed to other lines of chemotherapy or immunotherapy.